Marina Roy Luzarraga
A5042843133- Glioma Diagnosis and Treatment
- DNA Repair Mechanisms
- Cancer Genomics and Diagnostics
- Ubiquitin and proteasome pathways
- Genetic Neurodegenerative Diseases
Mutations in the ATM gene are common multiple cancers, but clinical studies of therapies targeting ATM-aberrant cancers have yielded mixed results. Refinement loss function (LOF) as a predictive biomarker response is urgently needed.
<div>AbstractPurpose:<p>Mutations in the <i>ATM</i> gene are common multiple cancers, but clinical studies of therapies targeting ATM-aberrant cancers have yielded mixed results. Refinement ATM loss function (LOF) as a predictive biomarker response is urgently needed.</p>Experimental Design:<p>We present first disclosure and preclinical development novel, selective ATR inhibitor, ART0380, test its antitumor activity cancer models. To refine LOF biomarker,...
<div>AbstractPurpose:<p>Mutations in the <i>ATM</i> gene are common multiple cancers, but clinical studies of therapies targeting ATM-aberrant cancers have yielded mixed results. Refinement ATM loss function (LOF) as a predictive biomarker response is urgently needed.</p>Experimental Design:<p>We present first disclosure and preclinical development novel, selective ATR inhibitor, ART0380, test its antitumor activity cancer models. To refine LOF biomarker,...
<p>supplementary figures</p>
<p>supplementary figures</p>